C4 Therapeutics, Inc. (CCCC)Healthcare | Biotechnology | Watertown, United States | NasdaqGS
3.81 USD
-0.11
(-2.806%) ⇩
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:34 a.m. EDT
The investment case for C4 Therapeutics is severely compromised by a catastrophic multi-year price trajectory. Despite a recent technical bounce and positive news regarding pipeline developments, the stock has lost over 94% of its value since 2021, with the most recent annual return being a sharp decline of nearly 56%. This is not a temporary correction; it is a structural implosion where the market has repeatedly rejected the company's value proposition. Fundamentally, the business is bleeding cash with negative operating margins and no revenue growth, while the balance sheet remains fragile relative to the burn rate. The options market confirms this pessimism, with traders piling into deep out-of-the-money puts to insure against further losses. While the biotech sector often offers binary outcomes, the combination of deteriorating fundamentals, a broken price trend, and aggressive short-term hedging suggests this is a value trap rather than a turnaround opportunity. Investors should avoid this security until there is clear, sustained evidence of commercial success or a drastic reduction in burn rate. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.259477 |
| MSTL | 0.260157 |
| AutoARIMA | 0.264655 |
| MSTL_126 | 0.292372 |
| AutoTheta | 0.298489 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 27.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.090 |
| Excess Kurtosis | -1.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 24.951 |
| Revenue per Share | 0.36 |
| Market Cap | 421,261,120 |
| Forward P/E | -3.66 |
| Beta | 2.91 |
| Profit Margins | -297.76% |
| Website | https://www.c4therapeutics.com |
As of July 11, 2026, 6:34 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive put volume and open interest at strikes significantly below the current price ($1.00, $2.00, $3.00) across multiple expirations. While there is some call activity at higher strikes ($9.00) for later dates, the overwhelming sentiment is hedging against a collapse, with implied volatility spiking on deep out-of-the-money puts. The options market is pricing in a high probability of further decline rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8578199 |
| Address1 | 490 Arsenal Way |
| Address2 | Suite120 |
| All Time High | 51.21 |
| All Time Low | 1.06 |
| Ask | 4.83 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 3,876,560 |
| Average Daily Volume3 Month | 3,082,547 |
| Average Volume | 3,082,547 |
| Average Volume10Days | 3,876,560 |
| Beta | 2.91 |
| Bid | 2.85 |
| Bid Size | 2 |
| Book Value | 2.252 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.81 |
| Current Ratio | 9.005 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.97 |
| Day Low | 3.775 |
| Debt To Equity | 24.951 |
| Display Name | C4 Therapeutics |
| Earnings Timestamp | 1,778,589,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -101,203,000 |
| Ebitda Margins | -2.90304 |
| Enterprise To Ebitda | -2.411 |
| Enterprise To Revenue | 7.0 |
| Enterprise Value | 244,037,120 |
| Eps Current Year | -0.956 |
| Eps Forward | -1.04 |
| Eps Trailing Twelve Months | -1.1 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.7775 |
| Fifty Day Average Change | 0.03250003 |
| Fifty Day Average Change Percent | 0.008603581 |
| Fifty Two Week Change Percent | 85.78199 |
| Fifty Two Week High | 5.17 |
| Fifty Two Week High Change | -1.3600001 |
| Fifty Two Week High Change Percent | -0.26305613 |
| Fifty Two Week Low | 1.69 |
| Fifty Two Week Low Change | 2.12 |
| Fifty Two Week Low Change Percent | 1.2544378 |
| Fifty Two Week Range | 1.69 - 5.17 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,601,645,400,000 |
| Float Shares | 83,714,866 |
| Forward Eps | -1.04 |
| Forward P E | -3.6634617 |
| Free Cashflow | -53,370,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 104 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.78339994 |
| Gross Profits | 27,310,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00929 |
| Held Percent Institutions | 0.85310996 |
| Implied Shares Outstanding | 110,567,222 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-10-02 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. |
| Long Name | C4 Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 421,261,120 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_321572356 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -103,801,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 421,261,115 |
| Number Of Analyst Opinions | 6 |
| Open | 3.96 |
| Operating Cashflow | -95,353,000 |
| Operating Margins | -4.51642 |
| Payout Ratio | 0.0 |
| Phone | 617 231 0700 |
| Pre Market Change | 0.030699968 |
| Pre Market Change Percent | 0.80577344 |
| Pre Market Price | 3.8407 |
| Pre Market Time | 1,784,112,251 |
| Previous Close | 3.9199998 |
| Price Eps Current Year | -3.9853556 |
| Price Hint | 4 |
| Price To Book | 1.6918294 |
| Price To Sales Trailing12 Months | 12.0840225 |
| Profit Margins | -2.9775698 |
| Quick Ratio | 8.755 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.109999895 |
| Regular Market Change Percent | -2.80612 |
| Regular Market Day High | 3.97 |
| Regular Market Day Low | 3.775 |
| Regular Market Day Range | 3.775 - 3.97 |
| Regular Market Open | 3.96 |
| Regular Market Previous Close | 3.9199998 |
| Regular Market Price | 3.81 |
| Regular Market Time | 1,784,059,201 |
| Regular Market Volume | 3,046,515 |
| Return On Assets | -0.19878 |
| Return On Equity | -0.48348 |
| Revenue Growth | -0.15 |
| Revenue Per Share | 0.36 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 110,567,222 |
| Shares Percent Shares Out | 0.22610001 |
| Shares Short | 24,997,175 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 21,650,001 |
| Short Name | C4 Therapeutics, Inc. |
| Short Percent Of Float | 0.22760001 |
| Short Ratio | 7.08 |
| Source Interval | 15 |
| State | MA |
| Symbol | CCCC |
| Target High Price | 30.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 13.33333 |
| Target Median Price | 11.0 |
| Total Cash | 235,671,008 |
| Total Cash Per Share | 2.131 |
| Total Debt | 58,447,000 |
| Total Revenue | 34,861,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.1 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.76085 |
| Two Hundred Day Average Change | 1.04915 |
| Two Hundred Day Average Change Percent | 0.38000977 |
| Type Disp | Equity |
| Volume | 3,046,515 |
| Website | https://www.c4therapeutics.com |
| Zip | 2,472 |